A Finnish startup that uses 3D printing to automate the preparation of personalised medications has closed a €12 million ($14 million) Series A round. CurifyLabs, founded in Helsinki in 2021, will use the funding to expand its US presence, build out supply chain infrastructure, and push forward product development.
The round was co-led by Sandwater and HealthCap, with Tesi (Finnish Industry Investment Ltd.) and existing backers including Lifeline Ventures also participating. It comes just over a year after the company raised €6.7 million in May 2025, signalling growing investor confidence in automated pharmacy technology.
“This investment reflects the conviction our partners have in what we’re building,” said Charlotta Topelius, CEO and founder of CurifyLabs. “We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”
How does it work?
CurifyLabs makes a system called the Compounding System Solution, or CSS. It combines proprietary software, GMP-manufactured excipient bases (the inactive ingredients used to carry active drugs), and 3D printing hardware to automate how pharmacies prepare custom-dose medications.
Instead of mixing compounds by hand, pharmacy staff use the CurifyLabs platform to produce personalised doses with greater speed and consistency. The company’s latest hardware, the PharmaPrinter Aurum, can reportedly compound medications up to nine times faster than manual processes.
The platform is ISO 13485 certified and built to comply with FDA 503A and 503B standards for non-sterile compounding, which are the two main regulatory frameworks covering pharmacy compounding in the United States.
Why does it matter?
Medication compounding, the process of preparing custom formulations for individual patients, is a niche but important part of healthcare. It covers cases where a standard commercial drug doesn’t work for a patient, whether because of allergies, dosage requirements, or the need for a different delivery method.
The problem is that manual compounding is slow, error-prone, and hard to scale. Pharmacies doing it by hand face consistency and safety challenges. Automating that process is what CurifyLabs is betting on.
The results so far suggest there’s real demand. Pharmacies in 21 US states and across Europe already use the company’s system to compound and dispense thousands of doses every day.
“CurifyLabs has built something rare, technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on,” said Morten E. Iversen, partner at Sandwater.
The context
CurifyLabs is raising into a busy moment for European health technology funding. A wave of similar deals has closed in 2026 across personalised health, diagnostics, surgical tools, and healthcare supply chains:
- Rem3dy Health raised €16 million for personalised health expansion
- ShanX Medtech secured €24 million for antimicrobial-susceptibility diagnostics
- Xyall closed a €7.6 million round for automated molecular pathology
- SamanTree Medical got €20 million from the EIB for surgical imaging
- BioLamina secured a €20 million EIB loan for cell-therapy infrastructure
- Astral Systems raised €26 million for medical isotope supply
Together, those rounds plus CurifyLabs’ new raise add up to roughly €149 million in disclosed funding across the sector in 2026 alone. That points to sustained investor appetite for companies rebuilding the physical and digital plumbing of healthcare, not just developing new drugs.
For Finland specifically, CurifyLabs’ US traction is a useful proof point. “Their growth in the US is further proof that Finnish health technology can compete and win on the world stage,” said Joni Karsikas, Investment Director at Tesi.
HealthCap partner Daniel Karsberg, whose firm has backed more than 136 life sciences companies over nearly three decades, pointed to the team’s ability to combine scientific depth with real-world execution as the deciding factor in joining the round.